The Imugene share price just leapt 10%. Here's why the ASX biotech stock is rocketing

Imugene shares are rising fast on Monday.

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Imugene Ltd (ASX: IMU) share price is soaring higher today.

Shares in the ASX biotechnology company closed on Friday trading for 4.8 cents. At the time of writing, shares are changing hands for 5.3 cents apiece, up 10.4%.

For some context, the All Ordinaries Index (ASX: XAO) is up 0.2% at this same time.

Here's what's spurring ASX investor interest today.

What's piquing ASX investor interest?

The Imugene share price is off to the races after the clinical-stage immuno-oncology company released a positive update on an ongoing clinical trial.

Imugene's Phase 1 MAST (Metastatic Advanced Solid Tumours) trial is evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA).

The trial commenced in May 2022. Management expects it to run for around 24 months, with funding coming from existing budgets and resources.

Patients in the study are given either CF33-hNIS alone, or in combination with pembrolizumab, either intravenously or intratumorally.

Among the early results that look to be stirring up excitement, Imugene reported that six patients with gastrointestinal cancers who received CF33-hNIS alone – including 2 colorectal cancer, 2 bile duct, 1 pancreatic and 1 liver cancer – "showed positive treatment effects", with a disease control rate of 75%.

Commenting on the results sending the Imugene share price sharply higher today, CEO Leslie Chong said, "Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development."

Chong added:

The early positive response data we are seeing at the mid-dose level in hard-to-treat bile duct cancer suggests that VAXINIA may be a potent anti-cancer drug as we interrogate higher dose levels. With no adverse safety signals, thus allowing us to dose higher, VAXINIA will have a very high therapeutic window which is valuable in oncology drug development.

Overall, the ongoing study aims to recruit cancer patients across some 10 trial sites in the United States and Australia.

Imugene share price snapshot

Despite the welcome lift today, the Imugene share price remains down 61% in 2023.

Shares are down a precipitous 73% over 12 months. Though investors who bought shares five years ago will still be sitting on gains of 170%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientist with headache, stress and fatigue with woman, overworked with overtime for science breakthrough. Medical research, scientific innovation and senior female, burnout and migraine in lab.
Healthcare Shares

Why is the Mesoblast share price in a trading halt?

Is Mesoblast raising funds again? Let's find out.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

The CSL share price return tripled the ASX 200 in November

November saw a very healthy return for CSL shares.

Read more »

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Share Market News

Here's why you might have just bought Healius shares

Two of the most popular super funds just loaded up on this healthcare stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Here's why this ASX 200 healthcare stock is roaring 13% higher on Wednesday

This healthcare company is outperforming every other stock within the ASX 200 today.

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop
Opinions

Could CSL stock be a millionaire-maker at $261

Does the exceptional biotech company still harness the power to make an investment today worth a million in the future?

Read more »

Two happy scientists analysing test results in a lab
Healthcare Shares

Why are Mesoblast shares charging 5% higher today?

This beaten down biotech is having a strong session. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Healius share price rallies amid corporate reset

An outgoing chair and a revitalised balance sheet. Healius is undergoing a makeover.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Imugene share price jumps 32% on FDA news

Here's why this biotech is having a strong start to the session.

Read more »